Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus heart risk: new study seeks better prediction tools

NCT ID NCT04276701

Ongoing Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 500 adults with lupus to see if certain immune markers can better predict who will develop heart disease. Participants give blood samples, have ultrasound scans of their neck arteries, and fill out diet and exercise questionnaires. The goal is to improve how doctors assess cardiovascular risk in lupus patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to identify lupus patients at high risk for heart disease, enabling earlier prevention.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change patient care, and the biomarkers studied may not prove useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

  • AP-HP - Hôpital Cochin - service de Médecine Interne

    Paris, France

  • CHRU de Lille - service de Médecine Interne

    Lille, France

  • CHU de Bordeaux - service de médecine interne

    Bordeaux, France

  • CHU de Brest - service de rhumatologie

    Brest, France

  • CHU de Strasbourg - service d'Immunologie Clinique

    Strasbourg, France

  • Universität Freiburg

    Freiburg im Breisgau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.